219 related articles for article (PubMed ID: 31736357)
1. Results of the FUEL Trial.
Goldberg DJ; Zak V; Goldstein BH; Schumacher KR; Rhodes J; Penny DJ; Petit CJ; Ginde S; Menon SC; Kim SH; Kim GB; Nowlen TT; DiMaria MV; Frischhertz BP; Wagner JB; McHugh KE; McCrindle BW; Shillingford AJ; Sabati AA; Yetman AT; John AS; Richmond ME; Files MD; Payne RM; Mackie AS; Davis CK; Shahanavaz S; Hill KD; Garg R; Jacobs JP; Hamstra MS; Woyciechowski S; Rathge KA; McBride MG; Frommelt PC; Russell MW; Urbina EM; Yeager JL; Pemberton VL; Stylianou MP; Pearson GD; Paridon SM;
Circulation; 2020 Feb; 141(8):641-651. PubMed ID: 31736357
[TBL] [Abstract][Full Text] [Related]
2. ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Kim KH; Kim HK; Hwang IC; Lee SP; Cho HJ; Kang HJ; Kim YJ; Sohn DW
Trials; 2013 Jun; 14():188. PubMed ID: 23799908
[TBL] [Abstract][Full Text] [Related]
3. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.
Goldberg DJ; French B; McBride MG; Marino BS; Mirarchi N; Hanna BD; Wernovsky G; Paridon SM; Rychik J
Circulation; 2011 Mar; 123(11):1185-93. PubMed ID: 21382896
[TBL] [Abstract][Full Text] [Related]
4. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
5. The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis.
Goldberg DJ; Hu C; Lubert AM; Rathod RH; Penny DJ; Petit CJ; Schumacher KR; Ginde S; Williams RV; Yoon JK; Kim GB; Nowlen TT; DiMaria MV; Frischhertz BP; Wagner JB; McHugh KE; McCrindle BW; Cartoski MJ; Detterich JA; Yetman AT; John AS; Richmond ME; Yung D; Payne RM; Mackie AS; Davis CK; Shahanavaz S; Hill KD; Almaguer M; Zak V; McBride MG; Goldstein BH; Pearson GD; Paridon SM;
Pediatr Cardiol; 2023 Dec; 44(8):1691-1701. PubMed ID: 37382636
[TBL] [Abstract][Full Text] [Related]
6. Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial.
Goldberg DJ; Zak V; Goldstein BH; McCrindle BW; Menon SC; Schumacher KR; Payne RM; Rhodes J; McHugh KE; Penny DJ; Trachtenberg F; Hamstra MS; Richmond ME; Frommelt PC; Files MD; Yeager JL; Pemberton VL; Stylianou MP; Pearson GD; Paridon SM;
Am Heart J; 2018 Jul; 201():1-8. PubMed ID: 29910047
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation.
Edelson JB; Zak V; Goldberg D; Fleming G; Mackie AS; Patel JK; Files M; Downing T; Richmond M; Acheampong B; Cartoski M; Detterich J; McCrindle B; McHugh K; Hansen JE; Wagner J; Maria MD; Weingarten A; Nowlen T; Yoon JK; Kim GB; Williams R; Whitehill R; Kirkpatrick E; Yin S; Ermis P; Lubert AM; Stylianou M; Freemon D; Hu C; Garuba OD; Frommelt P; Goldstein BH; Paridon S; Garg R;
Am J Cardiol; 2024 Jan; 210():183-187. PubMed ID: 37918818
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Chang HJ; Song S; Chang SA; Kim HK; Jung HO; Choi JH; Lee JS; Kim KH; Jeong JO; Lee JH; Kim DK
Clin Ther; 2019 Aug; 41(8):1499-1507. PubMed ID: 31202506
[TBL] [Abstract][Full Text] [Related]
9. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants.
Di Maria MV; Goldberg DJ; Zak V; Hu C; Lubert AM; Dragulescu A; Mackie AS; McCrary A; Weingarten A; Parthiban A; Goot B; Goldstein BH; Taylor C; Lindblade C; Petit CJ; Spurney C; Harrild DM; Urbina EM; Schuchardt E; Beom Kim G; Kyoung Yoon J; Colombo JN; Files MD; Schoessling M; Ermis P; Wong PC; Garg R; Swanson SK; Menon SC; Srivastava S; Thorsson T; Johnson TR; Krishnan US; Paridon SM; Frommelt PC;
Circ Cardiovasc Imaging; 2022 Nov; 15(11):e013676. PubMed ID: 36378780
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.
Butts R; Atz AM; BaezHernandez N; Sutcliffe D; Reisch J; Mahony L
Pediatr Cardiol; 2021 Apr; 42(4):934-941. PubMed ID: 33585998
[TBL] [Abstract][Full Text] [Related]
12. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
Hebert A; Mikkelsen UR; Thilen U; Idorn L; Jensen AS; Nagy E; Hanseus K; Sørensen KE; Søndergaard L
Circulation; 2014 Dec; 130(23):2021-30. PubMed ID: 25446057
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.
Goldberg DJ; Zak V; Goldstein BH; Chen S; Hamstra MS; Radojewski EA; Maunsell E; Mital S; Menon SC; Schumacher KR; Payne RM; Stylianou M; Kaltman JR; deVries TM; Yeager JL; Paridon SM;
Am Heart J; 2017 Jun; 188():42-52. PubMed ID: 28577680
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
[TBL] [Abstract][Full Text] [Related]
16. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial.
Oh HC; Cheon YK; Cho YD; Do JH
Gastrointest Endosc; 2011 Sep; 74(3):556-62. PubMed ID: 21802079
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.
Park HJ; Park JK; Park K; Min K; Park NC
J Sex Med; 2010 Jun; 7(6):2209-2216. PubMed ID: 20412426
[TBL] [Abstract][Full Text] [Related]
18. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
[TBL] [Abstract][Full Text] [Related]
19. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus.
Moon du G; Yang DY; Lee CH; Ahn TY; Min KS; Park K; Park JK; Kim JJ
J Sex Med; 2011 Jul; 8(7):2048-61. PubMed ID: 21554549
[TBL] [Abstract][Full Text] [Related]
20. Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial.
Park SJ; Park JJ; Choi DJ; Chun EJ; Choi SI; Kim SM; Jang SY; Ahn S; Choe YH
Trials; 2014 Aug; 15():333. PubMed ID: 25154607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
